NCT00812240 2023-02-01
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
Phase 3 Terminated
Clinical Trials
11 trialsNCT00324987 2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00585221 2017-02-10
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
University of Utah
Phase 2 Terminated
NCT00009906 2014-12-23
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT01031628 2013-09-09
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Sarcoma Alliance for Research through Collaboration
Phase 3 Terminated
NCT00091078 2013-06-05
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00956072 2012-09-24
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00427583 2012-08-07
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Novartis
Phase 2/3 Terminated
NCT00573404 2011-11-16
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT00372567 2011-03-17
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
Phase 3 Terminated